S Truant1, O Scatton2, S Dokmak3, J-M Regimbeau4, V Lucidi5, A Laurent6, R Gauzolino7, C Castro Benitez8, A Pequignot4, V Donckier5, C Lim6, M-L Blanleuil7, R Brustia2, Y-P Le Treut9, O Soubrane2, D Azoulay6, O Farges3, R Adam8, F-R Pruvot10. 1. Department of Digestive Surgery and Transplantation, CHU, Univ Nord de France, Lille, France. Electronic address: stephanie.truant@chru-lille.fr. 2. Department of Hepatobiliary Surgery and Liver Transplant, St Antoine Hospital, France. 3. Department of Hepatopancreatobiliary Surgery and Liver Transplantation, Beaujon Hospital, Clichy, France. 4. Department of Digestive Surgery, Amiens University Medical Centre, Amiens, France. 5. Department of Abdominal Surgery and Transplantation, Hospital Erasme, Brussels University, Belgium. 6. Department of Digestive and Hepatobiliary Surgery, AP-HP, Henri Mondor University Hospital, Créteil, France. 7. Department of General and Visceral Surgery, University Hospital of Poitiers, France. 8. Hepatobiliary Centre, Paul Brousse Hospital, AP-HP, Univ Paris-Sud, Villejuif, France. 9. Department of Digestive Surgery and Liver Transplantation, AP-HM, La Conception Hospital, Aix-Marseille University, France. 10. Department of Digestive Surgery and Transplantation, CHU, Univ Nord de France, Lille, France.
Abstract
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was recently developed to induce rapid hypertrophy and reduce post-hepatectomy liver failure in patients with insufficient remnant liver volume (RLV). However, mortality rates >12% have been reported. This study aimed to analyze the perioperative course of ALPPS and to identify factors associated with morbi-mortality. METHODS: Between April 2011 and September 2013, 62 patients operated in 9 Franco-Belgian hepatobiliary centres underwent ALPPS for colorectal metastases (N = 50) or primary tumors, following chemotherapy (N = 50) and/or portal vein embolization (PVE; N = 9). RESULTS: Most patients had right (N = 31) or right extended hepatectomy (N = 25) (median RLV/body weight ratio of 0.54% [0.21-0.77%]). RLV increased by 48.6% [-15.3 to 192%] 7.8 ± 4.5 days after stage1, but the hypertrophy decelerated beyond 7 days. Stage2 was cancelled in 3 patients (4.8%) for insufficient hypertrophy, portal vein thrombosis or death and delayed to ≥9 days in 32 (54.2%). Overall, 25 patients (40.3%) had major complication(s) and 8 (12.9%) died. Fourteen patients (22.6%) had post-stage1 complication of whom 5 (35.7%) died after stage2. Factors associated with major morbi-mortality were obesity, post-stage1 biliary fistula or ascites, and infected and/or bilious peritoneal fluid at stage2. The latter was the only predictor of Clavien ≥3 by multivariate analysis (OR: 4.9; 95% CI: 1.227-19.97; p = 0.025). PVE did not impact the morbi-mortality rates but prevented major cytolysis that was associated with poor outcome. CONCLUSIONS: The inter-stages course was crucial in determining ALPPS outcome. The factors of high morbi-mortality rates associated with ALPPS are linked to the technique complexity.
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was recently developed to induce rapid hypertrophy and reduce post-hepatectomy liver failure in patients with insufficient remnant liver volume (RLV). However, mortality rates >12% have been reported. This study aimed to analyze the perioperative course of ALPPS and to identify factors associated with morbi-mortality. METHODS: Between April 2011 and September 2013, 62 patients operated in 9 Franco-Belgian hepatobiliary centres underwent ALPPS for colorectal metastases (N = 50) or primary tumors, following chemotherapy (N = 50) and/or portal vein embolization (PVE; N = 9). RESULTS: Most patients had right (N = 31) or right extended hepatectomy (N = 25) (median RLV/body weight ratio of 0.54% [0.21-0.77%]). RLV increased by 48.6% [-15.3 to 192%] 7.8 ± 4.5 days after stage1, but the hypertrophy decelerated beyond 7 days. Stage2 was cancelled in 3 patients (4.8%) for insufficient hypertrophy, portal vein thrombosis or death and delayed to ≥9 days in 32 (54.2%). Overall, 25 patients (40.3%) had major complication(s) and 8 (12.9%) died. Fourteen patients (22.6%) had post-stage1 complication of whom 5 (35.7%) died after stage2. Factors associated with major morbi-mortality were obesity, post-stage1 biliary fistula or ascites, and infected and/or bilious peritoneal fluid at stage2. The latter was the only predictor of Clavien ≥3 by multivariate analysis (OR: 4.9; 95% CI: 1.227-19.97; p = 0.025). PVE did not impact the morbi-mortality rates but prevented major cytolysis that was associated with poor outcome. CONCLUSIONS: The inter-stages course was crucial in determining ALPPS outcome. The factors of high morbi-mortality rates associated with ALPPS are linked to the technique complexity.
Authors: Pim B Olthof; Robert J S Coelen; Jimme K Wiggers; Bas Groot Koerkamp; Massimo Malago; Roberto Hernandez-Alejandro; Stefan A Topp; Marco Vivarelli; Luca A Aldrighetti; Ricardo Robles Campos; Karl J Oldhafer; William R Jarnagin; Thomas M van Gulik Journal: HPB (Oxford) Date: 2017-03-06 Impact factor: 3.647
Authors: Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien Journal: Nat Rev Gastroenterol Hepatol Date: 2020-07-17 Impact factor: 46.802
Authors: Eduardo de Santibañes; Fernando A Alvarez; Victoria Ardiles; Juan Pekolj; Martin de Santibañes Journal: Langenbecks Arch Surg Date: 2016-04-15 Impact factor: 3.445
Authors: T F Ulmer; C de Jong; A Andert; P Bruners; C M Heidenhain; W Schoening; M Schmeding; U P Neumann Journal: World J Surg Date: 2017-01 Impact factor: 3.352